PANDAR and nonpapillary renal cell carcinoma: Previous studies have reported that PANDAR was significantly upregulated in cholangiocarcinoma (CCA) patients21, bladder cancer patients22, clear cell renal cell carcinoma (ccRCC) patients23, hepatocellular carcinoma24 and colorectal cancer patients25.